These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36994209)

  • 1. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.
    Fleuren EDG; Vlenterie M; van der Graaf WTA
    Front Oncol; 2023; 13():1013359. PubMed ID: 36994209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
    Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
    Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
    Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers.
    Kokkali S; Kyriazoglou A; Mangou E; Economopoulou P; Panousieris M; Psyrri A; Ardavanis A; Vassos N; Boukovinas I
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
    Tian Z; Niu X; Yao W
    Front Oncol; 2020; 10():1642. PubMed ID: 32984034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).
    Anderson P; Kopp L; Anderson N; Cornelius K; Herzog C; Hughes D; Huh W
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1703-15. PubMed ID: 18922107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.
    Assi A; Farhat M; Hachem MCR; Zalaquett Z; Aoun M; Daher M; Sebaaly A; Kourie HR
    J Bone Oncol; 2023 Dec; 43():100511. PubMed ID: 38058514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and clinical relevance of MET and ALK in Ewing sarcomas.
    Fleuren ED; Roeffen MH; Leenders WP; Flucke UE; Vlenterie M; Schreuder HW; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
    Int J Cancer; 2013 Jul; 133(2):427-36. PubMed ID: 23335077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
    Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
    Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of venous thromboembolism and major bleeding in the clinical course of osteosarcoma and Ewing sarcoma.
    Kaptein FHJ; Stals MAM; Evenhuis RE; Gelderblom H; Huisman MV; Karis DSA; Noten RWD; Cannegieter SC; Speetjens FM; Verschoor AJ; Versteeg HH; van de Sande MAJ; Klok FA
    Thromb Res; 2023 Jan; 221():19-25. PubMed ID: 36435048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
    Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
    BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ewing and osteogenic sarcoma: evidence for multidisciplinary management.
    Sciubba DM; Okuno SH; Dekutoski MB; Gokaslan ZL
    Spine (Phila Pa 1976); 2009 Oct; 34(22 Suppl):S58-68. PubMed ID: 19829278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib as an emerging treatment for sarcoma.
    Schöffski P; Blay JY; Ray-Coquard I
    Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.
    Attia S; Bolejack V; Ganjoo KN; George S; Agulnik M; Rushing D; Loggers ET; Livingston MB; Wright J; Chawla SP; Okuno SH; Reinke DK; Riedel RF; Davis LE; Ryan CW; Maki RG
    Cancer Med; 2023 Jan; 12(2):1532-1539. PubMed ID: 35950293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
    Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
    Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.